|
1
|
Azzoli CG, Baker S Jr, Temin S, et al:
American Society of Clinical Oncology Clinical Practice Guideline
update on chemotherapy for stage IV non-small-cell lung cancer. J
Clin Oncol. 27:6251–6266. 2009. View Article : Google Scholar
|
|
2
|
Hirsch FR, Varella-Garcia M and Cappuzzo
F: Predictive value of EGFR and HER2 overexpression in advanced
non-small-cell lung cancer. Oncogene. 28:32–37. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ciardiello F and Tortora G: EGFR
antagonists in cancer treatment. N Engl J Med. 358:1160–1174. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hynes NE and Lane HA: ERBB receptors and
cancer: the complexity of targeted inhibitors. Nat Rev Cancer.
5:341–354. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mendelsohn J and Baselga J: Status of
epidermal growth factor receptor antagonists in the biology and
treatment of cancer. J Clin Oncol. 21:2787–2799. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kelly K, Chansky K, Gaspar LE, Albain KS,
Jett J, Ung YC, Lau DH, Crowley JJ and Gandara DR: Phase III trial
of maintenance gefitinib or placebo after concurrent
chemoradiotherapy and docetaxel consolidation in inoperable stage
III non-small-cell lung cancer: SWOG S0023. J Clin Oncol.
26:2450–2456. 2008. View Article : Google Scholar
|
|
7
|
Gatzemeier U, Pluzanska A, Szczesna A, et
al: Phase III study of erlotinib in combination with cisplatin and
gemcitabine in advanced non-small-cell lung cancer: the Tarceva
Lung Cancer Investigation Trial. J Clin Oncol. 25:1545–1552. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pirker R, Pereira JR, Szczesna A, von
Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT,
Ganul V, Roh JK, Bajetta E, O’Byrne K, de Marinis F, Eberhardt W,
Goddemeier T, Emig M and Gatzemeier U; FLEX Study Team. Cetuximab
plus chemotherapy in patients with advanced non-small-cell lung
cancer (FLEX): an open-label randomised phase III trial. Lancet.
373:1525–1531. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gazdar AF: Epidermal growth factor
receptor inhibition in lung cancer: the evolving role of
individualized therapy. Cancer Metastasis Rev. 29:37–48. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kosaka T, Yatabe Y, Endoh H, Yoshida K,
Hida T, Tsuboi M, Tada H, Kuwano H and Mitsudomi T: Analysis of
epidermal growth factor receptor gene mutation in patients with
non-small cell lung cancer and acquired resistance to gefitinib.
Clin Cancer Res. 12:5764–5769. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Balak MN, Gong Y, Riely GJ, Somwar R, Li
AR, Zakowski MF, Chiang A, Yang G, Ouerfelli O, Kris MG, Ladanyi M,
Miller VA and Pao W: Novel D761Y and common secondary T790M
mutations in epidermal growth factor receptor-mutant lung
adenocarcinomas with acquired resistance to kinase inhibitors. Clin
Cancer Res. 12:6494–6501. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kancha RK, von Bubnoff N, Peschel C and
Duyster J: Functional analysis of epidermal growth factor receptor
(EGFR) mutations and potential implications for EGFR targeted
therapy. Clin Cancer Res. 15:460–467. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pawson T: Specificity in signal
transduction: from phosphotyrosine-SH2 domain interactions to
complex cellular systems. Cell. 116:191–203. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Song S, Wientjes MG, Gan Y and Au JL:
Fibroblast growth factors: an epigenetic mechanism of broad
spectrum resistance to anticancer drugs. Proc Natl Acad Sci USA.
97:8658–8663. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Karajannis MA, Vincent L, Direnzo R,
Shmelkov SV, Zhang F, Feldman EJ, Bohlen P, Zhu Z, Sun H, Kussie P
and Rafii S: Activation of FGFR1beta signaling pathway promotes
survival, migration and resistance to chemotherapy in acute myeloid
leukemia cells. Leukemia. 20:979–986. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Abukhdeir AM and Park BH: P21 and p27:
roles in carcinogenesis and drug resistance. Expert Rev Mol Med.
10:e192008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gartel AL and Tyner AL: The role of the
cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer
Ther. 1:639–649. 2002.PubMed/NCBI
|
|
18
|
Sutter AP, Höpfner M, Huether A, Maaser K
and Scherübl H: Targeting the epidermal growth factor receptor by
erlotinib (Tarceva) for the treatment of esophageal cancer. Int J
Cancer. 118:1814–1822. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ferrandiz N, Martin-Perez J, Blanco R,
Donertas D, Weber A, Eilers M, Dotto P, Delgado MD and Leon J:
HCT116 cells deficient in p21(Waf1) are hypersensitive to tyrosine
kinase inhibitors and adriamycin through a mechanism unrelated to
p21 and dependent on p53. DNA Repair. 8:390–399. 2009. View Article : Google Scholar : PubMed/NCBI
|
